BioCentury
ARTICLE | Clinical News

Yeliva: Ph Ib/II started

January 24, 2017 2:03 AM UTC

RedHill began an open-label, dose-escalation, U.S. Phase Ib/II trial to evaluate 250, 500 and 750 mg oral Yeliva twice daily in up to 77 patients who were previously treated with proteasome inhibitors...